Palvella Therapeutics (PVLA) Return on Capital Employed Growth (3y) (2017 - 2026)
Palvella Therapeutics (PVLA) Return on Capital Employed Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | 4,893.00 |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | -494.00 |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -649.00 |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 4,853.00 |
| 10 | Palvella Therapeutics | 1.88 Bn | 1.61 Bn | - | 8,214.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,214.00 |
| Dec 31, 2025 | -280.00 |
| Sep 30, 2025 | 592.00 |
| Jun 30, 2025 | 1,559.00 |
| Mar 31, 2025 | 2,423.00 |
| Dec 31, 2024 | 1,456.00 |
| Sep 30, 2024 | 6,817.00 |
| Jun 30, 2024 | 3,687.00 |
| Mar 31, 2024 | 6,097.00 |
| Dec 31, 2023 | 29.00 |
| Sep 30, 2023 | -5,893.00 |
| Jun 30, 2023 | -6,105.00 |
| Mar 31, 2023 | -9,386.00 |
| Dec 31, 2022 | -4,492.00 |
| Sep 30, 2022 | -1,284.00 |
| Jun 30, 2022 | -705.00 |
| Mar 31, 2022 | -1,612.00 |
| Dec 31, 2021 | -1,653.00 |
| Sep 30, 2021 | -3,838.00 |
| Jun 30, 2021 | -4,376.00 |